Company: SCLXW
Filing Date: 2025-09-29
Form Type: 424B3
Source: 0001193125-25-221018
Chunk: 49

Company: Scilex Holding Co
Filing Date: 2025-09-29
Form: 424B3
Chunk 49
---
 state securities laws.

This press release shall not constitute an offer to
sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.

Page | 1

Scilex has engaged Biconomy.com (“Biconomy”) to collaborate on future crypto currency strategies which
includes crypto currency reserve build up, treasury management, and strategy implementation. Biconomy will provide professional services to assist Scilex’s crypto market entry. “I am very excited to work with Scilex on their next
endeavor in the crypto space. The experience, forward-thinking, and the services that we have in the crypto space will prove to be a valuable asset to Scilex in various crypto currency projects”, said Dmitry Sheludko, CEO of Bioconomy.com.

JW Capital Securities Limited served as the financial advisor for this transaction.

For more information on Scilex Holding Company, refer to www.scilexholding.com

For
more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com

For more information on
ZTlido including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba, including Full Prescribing Information, refer to www.gloperba.com.

About Scilex Holding Company

Scilex is an
innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and
cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to
advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the
U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain;
(ii) ELYXYB, a potential first-line treatment and